Mumps
Mumps virus
Mumps Vaccine
Rubella
Measles
Rubella Vaccine
Orchitis
Rubulavirus
Measles Vaccine
Meningitis, Aseptic
Encyclopedias as Topic
Epididymitis
Mumps and mumps vaccine: a global review. (1/298)
Mumps is an acute infectious disease caused by a paramyxovirus. Although the disease is usually mild, up to 10% of patients can develop aseptic meningitis; a less common but more serious complication is encephalitis, which can result in death or disability. Permanent deafness, orchitis, and pancreatitis are other untoward effects of mumps. Based on data reported to WHO up to April 1998, mumps vaccine is routinely used by national immunization programmes in 82 countries/areas: 23 (92%) of 25 developed countries, 19 (86%) of 22 countries with economies in transition (mainly the Newly Independent States of the former Soviet Union), and 40 (24%) of 168 developing countries. Countries that have achieved high coverage have shown a rapid decline in mumps morbidity. Furthermore, in many of these countries, mumps-associated encephalitis and deafness have nearly vanished. This review considers the disease burden due to mumps; summarizes studies on the immunogenicity, efficacy, and safety of different strains of mumps vaccine; and highlights lessons learned about implementing mumps immunization in different countries. Countries already using mumps vaccine should monitor immunization coverage and establish routine mumps surveillance with investigation of outbreaks. Where mumps is targeted for elimination, countries need to add a second dose of mumps vaccine for children, keeping in mind that the disease may still occur in susceptible adults. (+info)The mumps virus neurovirulence safety test in Rhesus monkeys: a comparison of mumps virus strains. (2/298)
Wild type mumps viruses are highly neurotropic and a frequent cause of aseptic meningitis in unvaccinated humans. To test whether attenuated mumps viruses used in the manufacture of mumps vaccines have neurovirulent properties, a monkey neurovirulence safety test (MNVT) is performed. However, results with several mumps virus MNVTs have raised questions as to whether the test can reliably discriminate neurovirulent from nonneurovirulent mumps virus strains. Here, various mumps virus strains representing a wide range of neuropathogenicity were tested in a standardized MNVT. A trend of higher neurovirulence scores was observed in monkeys inoculated with wild type mumps virus versus vaccine strains, although differences were not statistically significant. Results indicated the need for further examination and refinement of the MNVT or for development of alternative MNVTs. (+info)Acute dysautonomia following mumps. (3/298)
Pure acute or subacute dysautonomia is a rare entity. Its etiology is as yet unknown. However, majority of these cases have a preceding viral infection such as herpes simplex, infectious mononucleosis, rubella or coxsackie B. A unique patient in whom acute dysautonomia followed mumps is reported. (+info)Genetic heterogeneity of mumps virus in the United Kingdom: identification of two new genotypes. (4/298)
A reverse transcriptase nested polymerase chain reaction (PCR) was developed to detect the small hydrophobic (SH) gene of mumps virus (MuV). Phylogenetic analysis was performed on the entire SH gene sequence (318 nucleotides) and the putative SH protein (57 amino acids). At least 4 MuV genotypes were identified in the United Kingdom between 1995 and 1998 by direct sequencing of 26 PCR amplicons from a variety of specimens. Comparison of these and GenBank sequences identified 2 new genotypes in the United Kingdom. The results suggest that, after the introduction of universal mumps vaccination in the United Kingdom in 1988, there appears to have been a switch from a predominant genotype to a heterogeneous group of strains. (+info)Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses. (5/298)
The decay of maternally derived antibodies to measles, mumps, and rubella viruses in Swiss infants was studied in order to determine the optimal time for vaccination. A total of 500 serum or plasma samples from infants up to 2 years of age were tested by enzyme-linked immunosorbent assay and fluorescent-antibody testing. The decline of antibody prevalence was slowest against the measles virus. By 9 to 12 months of age, only 5 of 58 (8.6%; 95% CI, 2.9 to 19.0) infants were antibody positive for the measles virus, and only 2 had levels above 200 mIU/ml. Mumps and rubella virus antibody seropositivity was lowest at 9 to 12 months of age with 3 of 58 (5. 2%; 95% CI, 1.1 to 14.4) infants and at 12 to 15 months with 1 of 48 (2.1%; 95% CI, 0.1 to 11.1) infants, respectively. Concentrations of passively acquired antibodies decreased rapidly within the first 6 months of life. We observed no significant differences in antibody prevalence or concentration according to gender in any age group. In conclusion, MMR vaccination at 12 instead of 15 months of age could reduce the pool of susceptible subjects in infancy and support the efforts to eliminate these infections, particularly in combination with a second vaccine dose before school entry. (+info)Infection with wild-type mumps virus in army recruits temporally associated with MMR vaccine. (6/298)
Four cases of mumps were reported among 180 army recruits who had received MMR vaccine 16 days earlier. Mumps serology, salivary mumps IgM and PCR tests for the SH gene were performed on the 4 cases and on 5 control recruits who remained well. PCR products were sequenced and the sequences compared to those of wild type and vaccine strains of mumps. Further salivary mumps IgM tests were performed on the remaining 171 recruits. Mumps infection was confirmed in the 4 cases but not in the 5 controls. The controls had serological evidence of prior immunity. The SH gene sequence found in the 4 cases was wild type. Saliva tests identified 2 additional recruits with mumps IgM, one of whom had presented with suspected mumps 2 days before the MMR vaccine was given. Thus 6 (5 symptomatic and 1 asymptomatic) cases of mumps in army recruits recently receiving MMR vaccine were not due to the vaccine but to coincidental infection with wild-type mumps virus. The probable index case was revealed by salivary mumps IgM tests. This study highlights the importance of appropriate investigation of illness associated with MMR vaccination. (+info)Nested PCR for rapid detection of mumps virus in cerebrospinal fluid from patients with neurological diseases. (7/298)
In this study, we have developed a reverse transcription (RT)-nested polymerase chain reaction (n-PCR) for the detection of mumps virus RNA in cerebrospinal fluid (CSF) from patients with neurological infections. A specific 112-bp fragment was amplified by this method with primers from the nucleoprotein of the mumps virus genome. The mumps virus RT-n-PCR was capable of detecting 0.001 PFU/ml and 0.005 50% tissue culture infective dose/ml. This method was found to be specific, since no PCR product was detected in each of the CSF samples from patients with proven non-mumps virus-related meningitis or encephalitis. Mumps virus RNA was detected in all 18 CSF samples confirmed by culture to be infected with mumps virus. Positive PCR results were obtained for the CSF of 26 of 28 patients that were positive for signs of mumps virus infection (i.e., cultivable virus from urine or oropharyngeal samples or positivity for anti-mumps virus immunoglobulin M) but without cultivable virus in their CSF. Overall, mumps virus RNA was detected in CSF of 96% of the patients with a clinical diagnosis of viral central nervous system (CNS) disease and confirmed mumps virus infection, while mumps virus was isolated in CSF of only 39% of the patients. Furthermore, in a retrospective study, we were able to detect mumps virus RNA in 25 of 55 (46%) CSF samples from patients with a clinical diagnosis of viral CNS disease and negative laboratory evidence of viral infection including mumps virus infection. The 25 patients represent 12% of the 236 patients who had a clinical diagnosis of viral CNS infections and whose CSF was examined at our laboratory for a 2-year period. The findings confirm the importance of mumps virus as a causative agent of CNS infections in countries with low vaccine coverage rates. In summary, our study demonstrates the usefulness of the mumps virus RT-n-PCR for the diagnosis of mumps virus CNS disease and suggests that this assay may soon become the "gold standard" test for the diagnosis of mumps virus CNS infection. (+info)A secondary school outbreak of mumps following the childhood immunization programme in England and Wales. (8/298)
Since the introduction of routine measles, mumps and rubella immunization for children in England and Wales in 1988, the incidence of mumps has declined steadily. We describe an outbreak of mumps in 1996 attacking 34 of a cohort of 98 schoolchildren born in 1982 and 1983. This is the largest outbreak in the UK since the introduction of the vaccine into the childhood immunization schedule. Salivary IgM assay was used as a simple, minimally invasive test to confirm the diagnosis. The occurrence of the outbreak demonstrates that British children who were just too old to receive mumps immunization in 1988 continue to be at risk of this disease as a result of diminished natural exposure. Further cases and outbreaks in this cohort are to be expected. Cohorts born before 1982 appear to be at less risk, presumably because of naturally acquired infection before the introduction of immunization. (+info)Mumps is a viral infection that primarily affects the parotid salivary glands, causing them to swell and become painful. The medical definition of mumps is: "An acute infectious disease, caused by the mumps virus, characterized by painful enlargement of one or more of the salivary glands, especially the parotids."
The infection spreads easily through respiratory droplets or direct contact with an infected person's saliva. Symptoms typically appear 16-18 days after exposure and include fever, headache, muscle aches, tiredness, and swollen, tender salivary glands. Complications of mumps are rare but can be serious and include meningitis, encephalitis, deafness, and inflammation of the reproductive organs in males.
Prevention is through vaccination with the measles-mumps-rubella (MMR) vaccine, which is part of routine childhood immunization schedules in many countries.
The Mumps virus is a single-stranded, negative-sense RNA virus that belongs to the Paramyxoviridae family and Rubulavirus genus. It is the causative agent of mumps, an acute infectious disease characterized by painful swelling of the salivary glands, particularly the parotid glands.
The Mumps virus has a spherical or pleomorphic shape with a diameter of approximately 150-250 nanometers. It is surrounded by a lipid bilayer membrane derived from the host cell, which contains viral glycoproteins that facilitate attachment and entry into host cells.
The M protein, located beneath the envelope, plays a crucial role in virus assembly and budding. The genome of the Mumps virus consists of eight genes encoding nine proteins, including two major structural proteins (nucleocapsid protein and matrix protein) and several non-structural proteins involved in viral replication and pathogenesis.
Transmission of the Mumps virus occurs through respiratory droplets or direct contact with infected saliva. After infection, the incubation period ranges from 12 to 25 days, followed by a prodromal phase characterized by fever, headache, malaise, and muscle pain. The characteristic swelling of the parotid glands usually appears 1-3 days after the onset of symptoms.
Complications of mumps can include meningitis, encephalitis, orchitis, oophoritis, pancreatitis, and deafness. Prevention relies on vaccination with the measles-mumps-rubella (MMR) vaccine, which is highly effective in preventing mumps and its complications.
The Mumps Vaccine is a biological preparation intended to induce immunity against mumps, a contagious viral infection that primarily affects the salivary glands. The vaccine contains live attenuated (weakened) mumps virus, which stimulates the immune system to develop a protective response without causing the disease.
There are two types of mumps vaccines available:
1. The Jeryl Lynn strain is used in the United States and is part of the Measles, Mumps, and Rubella (MMR) vaccine and the Measles, Mumps, Rubella, and Varicella (MMRV) vaccine. This strain is derived from a clinical isolate obtained from the throat washings of a child with mumps in 1963.
2. The Urabe AM9 strain was used in some countries but has been discontinued in many places due to an increased risk of meningitis as a rare complication.
The MMR vaccine is typically given to children at 12-15 months of age and again at 4-6 years of age, providing long-lasting immunity against mumps in most individuals. The vaccine has significantly reduced the incidence of mumps and its complications worldwide.
The Measles-Mumps-Rubella (MMR) vaccine is a combination immunization that protects against three infectious diseases: measles, mumps, and rubella. It contains live attenuated viruses of each disease, which stimulate an immune response in the body similar to that produced by natural infection but do not cause the diseases themselves.
The MMR vaccine is typically given in two doses, the first at 12-15 months of age and the second at 4-6 years of age. It is highly effective in preventing these diseases, with over 90% effectiveness reported after a single dose and near 100% effectiveness after the second dose.
Measles is a highly contagious viral disease that can cause fever, rash, cough, runny nose, and red, watery eyes. It can also lead to serious complications such as pneumonia, encephalitis (inflammation of the brain), and even death.
Mumps is a viral infection that primarily affects the salivary glands, causing swelling and tenderness in the cheeks and jaw. It can also cause fever, headache, muscle aches, and fatigue. Mumps can lead to serious complications such as deafness, meningitis (inflammation of the membranes surrounding the brain and spinal cord), and inflammation of the testicles or ovaries.
Rubella, also known as German measles, is a viral infection that typically causes a mild fever, rash, and swollen lymph nodes. However, if a pregnant woman becomes infected with rubella, it can cause serious birth defects such as hearing impairment, heart defects, and developmental delays in the fetus.
The MMR vaccine is an important tool in preventing these diseases and protecting public health.
Parotitis is the medical term for inflammation of the parotid gland, which is one of the major salivary glands located in the face, near the ear. The condition can result from various causes, including bacterial or viral infections, autoimmune disorders, or obstruction of the salivary ducts.
Parotitis can cause symptoms such as pain, swelling, redness, and difficulty swallowing. In some cases, it may also lead to fever, chills, and general malaise. The diagnosis of parotitis typically involves a physical examination, medical history, and sometimes imaging studies or laboratory tests to identify the underlying cause. Treatment depends on the specific cause but may include antibiotics, pain relievers, hydration, and measures to improve salivary flow.
Rubella, also known as German measles, is a viral infection that primarily affects the skin and lymphatic system. It is caused by the rubella virus. The disease is typically mild with symptoms such as low-grade fever, sore throat, swollen glands (especially around the ears and back of the neck), and a rash that starts on the face and spreads to the rest of the body.
Rubella is preventable through vaccination, and it's part of the MMR (measles, mumps, and rubella) vaccine. It's crucial to get vaccinated against rubella because if a pregnant woman gets infected with the virus, it can cause serious birth defects in her unborn baby, including hearing impairment, eye abnormalities, heart problems, and developmental delays. This condition is called congenital rubella syndrome (CRS).
It's worth noting that rubella has been largely eliminated from many parts of the world due to widespread vaccination programs, but it still remains a public health concern in areas with low vaccination rates or where access to healthcare is limited.
Measles, also known as rubeola, is a highly infectious viral disease that primarily affects the respiratory system. It is caused by the measles virus, which belongs to the family Paramyxoviridae and the genus Morbillivirus. The virus is transmitted through direct contact with infected individuals or through airborne droplets released during coughing and sneezing.
The classic symptoms of measles include:
1. Fever: A high fever (often greater than 104°F or 40°C) usually appears before the onset of the rash, lasting for about 4-7 days.
2. Cough: A persistent cough is common and may become severe.
3. Runny nose: A runny or blocked nose is often present during the early stages of the illness.
4. Red eyes (conjunctivitis): Inflammation of the conjunctiva, the mucous membrane that covers the inner surface of the eyelids and the white part of the eye, can cause redness and irritation.
5. Koplik's spots: These are small, irregular, bluish-white spots with a red base that appear on the inside lining of the cheeks, usually 1-2 days before the rash appears. They are considered pathognomonic for measles, meaning their presence confirms the diagnosis.
6. Rash: The characteristic measles rash typically starts on the face and behind the ears, then spreads downward to the neck, trunk, arms, and legs. It consists of flat red spots that may merge together, forming irregular patches. The rash usually lasts for 5-7 days before fading.
Complications from measles can be severe and include pneumonia, encephalitis (inflammation of the brain), and ear infections. In rare cases, measles can lead to serious long-term complications or even death, particularly in young children, pregnant women, and individuals with weakened immune systems.
Vaccination is an effective way to prevent measles. The measles vaccine is typically administered as part of the Measles, Mumps, and Rubella (MMR) vaccine, which provides immunity against all three diseases.
Rubella vaccine is a preventive measure used to immunize individuals against rubella, also known as German measles. It contains inactivated or weakened forms of the rubella virus that stimulate an immune response when introduced into the body. The two types of rubella vaccines available are:
1. Live Attenuated Rubella Vaccine (RAV): This vaccine contains a weakened form of the rubella virus, which triggers an immune response without causing the disease. It is the most commonly used rubella vaccine and is often combined with measles and mumps vaccines to create the Measles-Mumps-Rubella (MMR) or Measles-Mumps-Rubella-Varicella (MMRV) vaccines.
2. Inactivated Rubella Vaccine: This vaccine contains a killed rubella virus, which is less commonly used but can still provide immunity against the disease.
The Centers for Disease Control and Prevention (CDC) recommends that children receive one dose of MMR vaccine at 12-15 months of age and another dose at 4-6 years of age. This schedule ensures optimal protection against rubella and other diseases included in the vaccines.
It is important to note that pregnant women should not receive the rubella vaccine, as it can potentially harm the developing fetus. Women who are planning to become pregnant should ensure they have had their rubella immunization before conceiving.
Orchitis is a medical condition characterized by inflammation of one or both testicles, usually caused by an infection. The most common cause of orchitis is a bacterial infection that spreads from the epididymis, resulting in a condition known as epididymo-orchitis. However, viral infections such as mumps can also lead to orchitis. Symptoms may include sudden and severe pain in the testicle(s), swelling, warmth, redness of the overlying skin, nausea, vomiting, and fever. Treatment typically involves antibiotics for bacterial infections and supportive care for symptom relief. If left untreated, orchitis can lead to complications such as infertility or testicular atrophy.
Rubulavirus is a genus in the family Paramyxoviridae, order Mononegavirales. It includes several viruses that primarily cause respiratory infections in humans and animals. The most well-known rubulaviruses affecting humans are the human parainfluenza viruses (HPIV) 2 and 4, which can cause croup and bronchitis, and mumps virus, which causes mumps. These viruses are typically spread through respiratory droplets and direct contact with infected individuals. They have enveloped, non-segmented, negative-sense RNA genomes.
Combined vaccines are defined in medical terms as vaccines that contain two or more antigens from different diseases, which are given to provide protection against multiple diseases at the same time. This approach reduces the number of injections required and simplifies the immunization schedule, especially during early childhood. Examples of combined vaccines include:
1. DTaP-Hib-IPV (e.g., Pentacel): A vaccine that combines diphtheria, tetanus, pertussis (whooping cough), Haemophilus influenzae type b (Hib) disease, and poliovirus components in one injection to protect against these five diseases.
2. MMRV (e.g., ProQuad): A vaccine that combines measles, mumps, rubella, and varicella (chickenpox) antigens in a single injection to provide immunity against all four diseases.
3. HepA-HepB (e.g., Twinrix): A vaccine that combines hepatitis A and hepatitis B antigens in one injection, providing protection against both types of hepatitis.
4. MenACWY-TT (e.g., MenQuadfi): A vaccine that combines four serogroups of meningococcal bacteria (A, C, W, Y) with tetanus toxoid as a carrier protein in one injection for the prevention of invasive meningococcal disease caused by these serogroups.
5. PCV13-PPSV23 (e.g., Vaxneuvance): A vaccine that combines 13 pneumococcal serotypes with PPSV23, providing protection against a broader range of pneumococcal diseases in adults aged 18 years and older.
Combined vaccines have been thoroughly tested for safety and efficacy to ensure they provide a strong immune response and an acceptable safety profile. They are essential tools in preventing various infectious diseases and improving overall public health.
A measles vaccine is a biological preparation that induces immunity against the measles virus. It contains an attenuated (weakened) strain of the measles virus, which stimulates the immune system to produce antibodies that protect against future infection with the wild-type (disease-causing) virus. Measles vaccines are typically administered in combination with vaccines against mumps and rubella (German measles), forming the MMR vaccine.
The measles vaccine is highly effective, with one or two doses providing immunity in over 95% of people who receive it. It is usually given to children as part of routine childhood immunization programs, with the first dose administered at 12-15 months of age and the second dose at 4-6 years of age.
Measles vaccination has led to a dramatic reduction in the incidence of measles worldwide and is considered one of the greatest public health achievements of the past century. However, despite widespread availability of the vaccine, measles remains a significant cause of morbidity and mortality in some parts of the world, particularly in areas with low vaccination coverage or where access to healthcare is limited.
Antibodies, viral are proteins produced by the immune system in response to an infection with a virus. These antibodies are capable of recognizing and binding to specific antigens on the surface of the virus, which helps to neutralize or destroy the virus and prevent its replication. Once produced, these antibodies can provide immunity against future infections with the same virus.
Viral antibodies are typically composed of four polypeptide chains - two heavy chains and two light chains - that are held together by disulfide bonds. The binding site for the antigen is located at the tip of the Y-shaped structure, formed by the variable regions of the heavy and light chains.
There are five classes of antibodies in humans: IgA, IgD, IgE, IgG, and IgM. Each class has a different function and is distributed differently throughout the body. For example, IgG is the most common type of antibody found in the bloodstream and provides long-term immunity against viruses, while IgA is found primarily in mucous membranes and helps to protect against respiratory and gastrointestinal infections.
In addition to their role in the immune response, viral antibodies can also be used as diagnostic tools to detect the presence of a specific virus in a patient's blood or other bodily fluids.
Aseptic meningitis is a type of meningitis (inflammation of the membranes covering the brain and spinal cord) that is not caused by bacterial infection. Instead, it can be due to viral infections, fungal infections, or non-infectious causes such as certain medications, chemical irritants, or underlying medical conditions. In aseptic meningitis, the cerebrospinal fluid (CSF) analysis may show increased white blood cells, typically lymphocytes, but no bacterial growth on culture. Common viral causes include enteroviruses, herpes simplex virus, and varicella-zoster virus. Treatment depends on the underlying cause and may include supportive care, antiviral medications, or immunosuppressive therapy in some cases.
An encyclopedia is a comprehensive reference work containing articles on various topics, usually arranged in alphabetical order. In the context of medicine, a medical encyclopedia is a collection of articles that provide information about a wide range of medical topics, including diseases and conditions, treatments, tests, procedures, and anatomy and physiology. Medical encyclopedias may be published in print or electronic formats and are often used as a starting point for researching medical topics. They can provide reliable and accurate information on medical subjects, making them useful resources for healthcare professionals, students, and patients alike. Some well-known examples of medical encyclopedias include the Merck Manual and the Stedman's Medical Dictionary.
Epididymitis is defined as the inflammation of the epididymis, a curved tube-like structure located at the back of the testicle that stores and transports sperm. The inflammation can result from infection, trauma, or other causes, and may cause symptoms such as pain, swelling, and tenderness in the scrotum. In some cases, epididymitis may also be associated with urinary tract infections, sexually transmitted infections, or other medical conditions. Treatment typically involves antibiotics to treat any underlying infection, as well as pain relief measures and supportive care to help reduce symptoms and promote healing.
The parotid gland is the largest of the major salivary glands. It is a bilobed, accessory digestive organ that secretes serous saliva into the mouth via the parotid duct (Stensen's duct), located near the upper second molar tooth. The parotid gland is primarily responsible for moistening and lubricating food to aid in swallowing and digestion.
Anatomically, the parotid gland is located in the preauricular region, extending from the zygomatic arch superiorly to the angle of the mandible inferiorly, and from the masseter muscle anteriorly to the sternocleidomastoid muscle posteriorly. It is enclosed within a fascial capsule and has a rich blood supply from the external carotid artery and a complex innervation pattern involving both parasympathetic and sympathetic fibers.
Parotid gland disorders can include salivary gland stones (sialolithiasis), infections, inflammatory conditions, benign or malignant tumors, and autoimmune diseases such as Sjögren's syndrome.